• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Conflicting Views On Corteva’s Seeds Split Quietly Rewriting The CTVA Risk Story?

    Simply Wall St·03/29/2026 06:10:48
    Listen to the news
    • In recent commentary, Jim Cramer said he would continue to own Corteva, while Hardman Johnston Global Equity Strategy exited its position, citing uncertainty over a potential separation of the Seeds and Crop Protection businesses and weaker agricultural fundamentals.
    • This contrast between a high-profile media endorsement and an institutional investor’s concern over farm economics and corporate direction has sharpened focus on Corteva’s longer-term business mix and resilience.
    • We’ll now examine how rising concern over a possible Seeds and Crop Protection split could reshape Corteva’s investment narrative and risk balance.

    Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

    Corteva Investment Narrative Recap

    To own Corteva, you need to believe in steady global demand for higher yielding seeds and effective crop protection, supported by the company’s innovation pipeline and cost discipline. The latest split speculation and mixed views from Jim Cramer and Hardman Johnston mainly sharpen attention on the biggest near term swing factor: how resilient farmer spending and margins will be if agricultural fundamentals stay soft, while the key risk remains pressure on Crop Protection pricing and mix.

    Against this backdrop, Corteva’s recent Etlas joint venture with bp to develop crop based feedstocks for sustainable aviation fuel ties directly into the longer term catalyst of growing demand for more sustainable agricultural inputs and biofuels. It also sits alongside Corteva’s ongoing dividend and buyback program, which could support returns if earnings track the company’s 2026 guidance and the Seeds and Crop Protection portfolio continues to benefit from premium trait and biological product launches.

    Yet behind the headlines, investors should also be aware of the tension between premium valuation and ongoing pricing pressure in Crop Protection...

    Read the full narrative on Corteva (it's free!)

    Corteva's narrative projects $19.2 billion revenue and $2.3 billion earnings by 2029.

    Uncover how Corteva's forecasts yield a $83.95 fair value, in line with its current price.

    Exploring Other Perspectives

    CTVA 1-Year Stock Price Chart
    CTVA 1-Year Stock Price Chart

    Six fair value estimates from the Simply Wall St Community span roughly US$53 to US$84 per share, showing how far apart views on Corteva can be. As you weigh those opinions, keep in mind that ongoing price pressure and competition in Crop Protection could matter just as much for future performance as any potential portfolio reshuffle.

    Explore 6 other fair value estimates on Corteva - why the stock might be worth as much as $83.95!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For Alternative Opportunities?

    Opportunities like this don't last. These are today's most promising picks. Check them out now:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.